BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38353987)

  • 1. Efficacy and Durability of Intravenous Ertapenem Therapy for Recalcitrant Hidradenitis Suppurativa.
    Nosrati A; Ch'en PY; Torpey ME; Shokrian N; Ball G; Benesh G; Andriano TM; Zhu TR; Heibel HD; Hosgood HD; Campton KL; Cohen SR
    JAMA Dermatol; 2024 Mar; 160(3):312-318. PubMed ID: 38353987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ertapenem - a potent treatment for clinical and quality of life improvement in patients with hidradenitis suppurativa.
    Braunberger TL; Nartker NT; Nicholson CL; Nahhas AF; Parks-Miller A; Hanna Z; Jayaprakash R; Ramesh MS; Rambhatla PV; Hamzavi IH
    Int J Dermatol; 2018 Sep; 57(9):1088-1093. PubMed ID: 29774531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients.
    Join-Lambert O; Coignard-Biehler H; Jais JP; Delage M; Guet-Revillet H; Poirée S; Duchatelet S; Jullien V; Hovnanian A; Lortholary O; Nassif X; Nassif A
    J Antimicrob Chemother; 2016 Feb; 71(2):513-20. PubMed ID: 26565016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab efficacy is inversely correlated with body mass index (BMI) in hidradenitis suppurativa.
    Nosrati A; Torpey ME; Shokrian N; Ch'en PY; Andriano TM; Benesh G; Heibel HD; Hosgood HD; Campton KL; Cohen SR
    Int J Dermatol; 2023 Jun; 62(6):764-769. PubMed ID: 36582044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
    Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
    Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.
    Rivera-Díaz R; Pozo T; Alfageme F; Díaz Ley B; Osorio GF; Chico R; Vilarrasa E; Silvente C; Ciudad Blanco C; Romaní J; Martorell A; Fernández P; Romero Ferreiro C; Molina Leyva A
    Actas Dermosifiliogr; 2023 Oct; 114(9):755-762. PubMed ID: 37331620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.
    Rivera-Díaz R; Pozo T; Alfageme F; Díaz Ley B; Osorio GF; Chico R; Vilarrasa E; Silvente C; Ciudad Blanco C; Romaní J; Martorell A; Fernández P; Romero Ferreiro C; Molina Leyva A
    Actas Dermosifiliogr; 2023 Oct; 114(9):T755-T762. PubMed ID: 37479135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Patient Satisfaction Associated With Intramuscular Triamcinolone Therapy for Acute Flares of Hidradenitis Suppurativa.
    Benesh G; Andriano TM; Hosgood HD; Cohen SR
    J Cutan Med Surg; 2023; 27(4):350-357. PubMed ID: 37461296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
    Glatt S; Jemec GBE; Forman S; Sayed C; Schmieder G; Weisman J; Rolleri R; Seegobin S; Baeten D; Ionescu L; Zouboulis CC; Shaw S
    JAMA Dermatol; 2021 Nov; 157(11):1279-1288. PubMed ID: 34406364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Balancing Ertapenem Therapy in Recalcitrant Hidradenitis Suppurativa With Antibiotic Stewardship.
    Naik HB
    JAMA Dermatol; 2024 Mar; 160(3):319. PubMed ID: 38353969
    [No Abstract]   [Full Text] [Related]  

  • 12. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa.
    Leslie KS; Tripathi SV; Nguyen TV; Pauli M; Rosenblum MD
    J Am Acad Dermatol; 2014 Feb; 70(2):243-51. PubMed ID: 24314876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Hidradenitis Suppurativa Disease Course During Pregnancy and Postpartum.
    Lyons AB; Peacock A; McKenzie SA; Jacobsen G; Naik HB; Shi VY; Hamzavi IH; Hsiao JL
    JAMA Dermatol; 2020 Jun; 156(6):681-685. PubMed ID: 32347884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial.
    Tzanetakou V; Kanni T; Giatrakou S; Katoulis A; Papadavid E; Netea MG; Dinarello CA; van der Meer JWM; Rigopoulos D; Giamarellos-Bourboulis EJ
    JAMA Dermatol; 2016 Jan; 152(1):52-59. PubMed ID: 26579854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clindamycin as unique antibiotic choice in Hidradenitis Suppurativa.
    Rosi E; Pescitelli L; Ricceri F; Di Cesare A; Novelli A; Pimpinelli N; Prignano F
    Dermatol Ther; 2019 Mar; 32(2):e12792. PubMed ID: 30515931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the Hidradenitis Suppurativa Investigator Global Assessment: A Novel Hidradenitis Suppurativa-Specific Investigator Global Assessment for Use in Interventional Trials.
    Garg A; Zema C; Ciaravino V; Rolleri R; Peterson L; Garcia L; Massaro T; Jemec GBE; Kirby JS; Thorlacius L; Ingram JR
    JAMA Dermatol; 2023 Jun; 159(6):606-612. PubMed ID: 37099284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
    Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
    J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of a multi-tiered treatment approach for intellectually and developmentally disabled patients with hidradenitis suppurativa.
    Nosrati A; Torpey ME; Andriano TM; Benesh G; Babbush KM; Hosgood HD; Campton KL; Cohen SR
    Arch Dermatol Res; 2023 Aug; 315(6):1827-1829. PubMed ID: 36745196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of topical resorcinol 15% versus topical clindamycin 1% in the management of mild-to-moderate hidradenitis suppurativa: A retrospective study.
    Molinelli E; Brisigotti V; Simonetti O; Sapigni C; D'Agostino GM; Rizzetto G; Giacchetti A; Offidani A
    Dermatol Ther; 2022 Jun; 35(6):e15439. PubMed ID: 35278025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: Clinical and ultrasound observations.
    Caposiena Caro RD; Cannizzaro MV; Botti E; Di Raimondo C; Di Matteo E; Gaziano R; Bianchi L
    J Am Acad Dermatol; 2019 May; 80(5):1314-1321. PubMed ID: 30502416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.